Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer

NCT02971761 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Androgen Receptor Positive
Estrogen Receptor Negative
HER2/Neu Negative
Metastatic Triple-Negative Breast Carcinoma
Progesterone Receptor Negative
Stage IV Breast Cancer AJCC v6 and v7

Interventions

DRUG: Enobosarm
OTHER: Laboratory Biomarker Analysis
BIOLOGICAL: Pembrolizumab

Sponsor

City of Hope Medical Center

Collaborators

[object Object]